DD 25

Drug Profile

DD 25

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator Fortuderm
  • Class Antipsoriatics
  • Mechanism of Action Serotonin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Plaque psoriasis

Most Recent Events

  • 23 Sep 2015 No recent reports of development identified - Phase-I/II for Plaque psoriasis in Israel (Topical)
  • 01 Oct 2012 Phase-I/II clinical trials in Plaque psoriasis in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top